The value of inflammatory parameters in the prognosis of malignant mesothelioma

Size: px
Start display at page:

Download "The value of inflammatory parameters in the prognosis of malignant mesothelioma"

Transcription

1 Clinical Report The value of inflammatory parameters in the prognosis of malignant mesothelioma Journal of International Medical Research 2014, Vol. 42(2) ! The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / imr.sagepub.com Ozlem Abakay 1, Abdullah Cetin Tanrikulu 1, Yilmaz Palanci 2 and Abdurrahman Abakay 1 Abstract Objective: This study investigated the relationship between potential prognostic parameters that may be associated with increased inflammation and survival in patients with malignant mesothelioma (MM). Methods: This retrospective study assessed potential prognostic parameters measured at the time of MM diagnosis. Data on asbestos exposure, histopathological subtype of MM and laboratory parameters were collected. Results: In 155 patients with MM (90 male), mean survival time was 13.9 months. In univariate analysis, age 60 years and neutrophil-to-lymphocyte ratio (NLR) 3 were associated with significantly shortened median survival times. In multivariate analysis, nonepithelial subtype, red cell distribution width (RDW) 20% and NLR 3 were associated with significantly shortened median survival times. Mortality rate was increased 2.77-, and 1.52-fold in patients with RDW 20%, NLR 3 and nonepithelial subtype, respectively. Nonepithelial subtype, white blood cell count ml and platelet-to-lymphocyte ratio 300 at baseline were associated with a heightened NLR value. Conclusions: The NLR and RDW were significant predictive factors for MM prognosis. Keywords Malignant mesothelioma, neutrophil-to-lymphocyte ratio, prognosis, red cell distribution width Date received: 27 May 2013; accepted: 16 June 2013 Introduction Malignant mesothelioma (MM) is a tumour with increasing incidence; 1 it is highly prevalent in the southeast region of Turkey because of environmental asbestos 1 Department of Chest Diseases, Dicle University, Diyarbakir, Turkey 2 Department of Public Health, Dicle University, Diyarbakir, Turkey exposure. 2 4 Although several treatment options have been used in patients with MM, the disease has a poor prognosis, with a mean survival time of only 12 months. 5 7 Corresponding author: Abdurrahman Abakay, Department of Chest Diseases, Dicle University, Diyarbakir 21100, Turkey. Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).

2 Abakay et al. 555 The European Organisation for Research and Treatment of Cancer (EORTC) and the Cancer and Leukemia Group B have devised two prognostic scoring systems for use in patients with MM, 8,9 which are based on several signs and symptoms of the disease. However, these scoring systems are not routinely used in MM prognosis because they are time consuming to perform. Therefore, in patients with MM, parameters that are useful, easy to measure and inexpensive to administer are needed for predicting prognosis. Local and systemic inflammatory responses are known to increase in patients with solid tumours, and are associated with prognosis Importantly, inflammation plays a critical role in the development of MM. 13 Moreover, during the MM disease process, patients show signs of increased inflammatory responses such as fever, sweats and weight loss. 14,15 Thus, markers of inflammation may have value in establishing the prognosis of patients with MM. Studies have identified the neutrophilto-lymphocyte ratio (NLR) and the plateletto-lymphocyte ratio (PLR) as measures of systemic inflammation; they are relatively inexpensive to perform and provide readily obtainable (and reproducible) markers that may be prognostic factors in patients with MM However, studies have shown conflicting results with NLR. For example, in one cohort of 30 patients with MM, NLR 5 was associated with poor MM prognosis. 20 In contrast, in 44 patients with MM treated with surgical procedures, NLR 5 was not found to be associated with MM prognosis. 21 Other potentially prognostic inflammatory markers are red cell distribution width (RDW) and mean platelet volume (MPV). RDW is a measure of the variability in the size of circulating erythrocytes, 22 and is routinely reported with complete blood count. Studies have suggested that RDW is increased in patients with cardiovascular and pulmonary diseases, with inflammation playing a key role MPV reflects platelet size, which is correlated with platelet function and activation: elevated MPV predicts high platelet activity and intensity of inflammation. 26 MPV values have been investigated in chronic inflammatory diseases, and increased values have been associated with conditions such as familial Mediterranean fever. 27,28 To our knowledge, no previous study has investigated the relationships between RDW or MPV and prognosis, in patients with MM. The aim of the present study was to investigate the relationship between potential prognostic indicators (including NLR, PLR, MPV, RDW and other variables) and survival, in patients with MM. Methods Study design This was a retrospective study conducted between 1 September 2012 and 1 December 2012, using data obtained prior to treatment and held in patients files. Local ethical approval was obtained from the Dicle University Medical Faculty Ethics Committee for Noninterventional Studies. Patients Eligible patients had MM that was diagnosed between November 2003 and November MM was confirmed histopathologically. Pathological diagnosis was obtained on biopsies, in line with recent international guidelines. 29 Asbestos exposure type and time, location of MM, histopathological subtype of MM and basic laboratory parameters were obtained from patients files held at the Research Hospital at Dicle University. Patients (or their next of

3 556 Journal of International Medical Research 42(2) kin) provided written informed consent for the data to be published. Potential prognostic parameters Details on the following potential prognostic parameters, measured at the time of diagnosis, were obtained from patients files: age <60 or 60 years; 5 sex; histopathological subtype of MM (epithelial or nonepithelial); haemoglobin level <10 g/l or 10 g/l; 17 serum lactate dehydrogenase (LDH) level <500 U/l or 500 U/l; 5,9 platelet count < /ml or /ml; 5 white blood cell (WBC) count <11 200/ml or /ml. 5 LDH level was determined in serum using heparin and citrate and an autoanalszer, (Architect 1600c, Abbott Laboratories, Irving, TX, USA). LDH level was measured in tubes with K2 ethylenediaminetetra-acetic acid. Haemogram parameters (including WBC, haemoglobin, platelet count, neutrophil and lymphocyte counts) were measured using Cell-Dyn 3700 (Abbott Diagnostics, Lake Forest, IL, USA). Assays were performed within 1 h of collection, after centrifugation of the paired specimens (1500 g for 10 min at room temperature).the NLR was determined by dividing the absolute neutrophil count by the absolute lymphocyte count. An NLR 3 was defined as a potential prognostic parameter, as described previously. 17,19 A similar calculation was performed to derive the PLR, with 300 being the cut-off level for positivity, in accordance with other literature. 18 MPV and RDW were calculated within the complete blood count; RDW % was considered as a potential prognostic parameter, as described previously. 24 It was not possible to identify any publications on the prognosis of MM in relation to MPV, but the median MPV value was 7.81 fl. Consequently, we considered MPV 8fl as a potential prognostic parameter. Assessment of the value of potential prognostic parameters Univariate and multivariate analyses were used to investigate the relationship between MM prognosis and the following 11 potential factors: age; sex; histopathological subtype; platelet count; WBC count; serum LDH level; NLR; PLR; MPV; haemoglobin level; RDW. Statistical analyses The mean SD values were obtained for continuous variables and 2 -test was used to examine categorical variables. Duration of survival and median and mean event times, with 95% confidence intervals (CI), were estimated according to the Kaplan Meier method. Median values were used in our definition of the cut-off limits. Duration of survival was defined as the period between time of diagnosis and time of death. If patients were still alive, survival was defined as the period between time of diagnosis and 1 November Cox proportional hazards regression model, with stratification for the clinical trial, was used for both the univariate and multivariate analyses. The univariate analysis examined the prognostic importance of all the aforementioned factors and the model was used to examine the variables. A two-sided test was used, with a 0.05 level of significance. Comparisons of overall survival were made using two-tailed log-rank tests. Only variables with P-values <0.10 in the univariate analysis were included in the final model for the multivariate analysis. In the Cox regression analysis, the backward conditional method was used. Significance was taken as P < Statistical analyses were performed using

4 Abakay et al. 557 SPSS Õ, version 15 (SPSS Inc., Chicago, IL, USA). Results Patients Information on basic laboratory parameters was available for 198 patients with MM. Of these, 36 patients were excluded from the study due to lack of sufficient data, and a further seven patients were excluded due to the presence of active infection and other comorbidities (chronic obstructive pulmonary disease, lung cancer, interstitial lung disease, pneumoconiosis). This left a study group of 155 patients with MM, of whom 32 were alive at the time of the study; the mean follow-up period was 13.9 months. The types of data available for analysis varied considerably, depending on the information retained in individual patient records. Patients had a mean SD age of years; 90 (58.1%) patients were male and 65 (42.0%) were female. There was limited information in the patient records on aspects such as comorbidities, treatment regimens and specific clinical findings. A total of 139 (89.7%) patients had pleural MM, 19 (12.3%) had peritoneal MM and one (0.6%) had pericardial MM; the numbers of peritoneal and pericardial MM were too low for statistical analysis. One hundred (64.5%) patients had epithelial subtype MM; six (3.9%) patients had sarcomatous subtype, six (3.9%) patients had mixed subtype and the subtype was unidentified in 43 (27.7%) patients. Environmental asbestos exposure was present in 100 (64.5%) patients and the mean exposure time in these patients was 31.2 years. Neutrophil-to-lymphocyte ratio values were (median 2.9). For other variables, PLR values were (median ), RDW values were (median 16.0) and MPV values were fl (median 7.81 fl). The mean SD survival time was months. Potential prognostic parameters Eleven potential prognostic factors were assessed in the univariate analysis (Table 1). Age 60 years, male sex, nonepithelial subtype, NLR 3 and RDW 20% were associated with shorter median survival times than age <60 years, female sex, epithelial subtype, NLR <3 and RDW <20%, respectively (P-values < 0.10); these factors were therefore included in the multivariate analysis. According to the multivariate analysis, median survival times were significantly shorter for nonepithelial subtype, RDW 20% and NLR 3 versus epithelial subtype, RDW <20% and NLR <3, respectively (all P < 0.05) (Table 1). Both the univariate and multivariate analyses revealed no associations between survival time and PLR 300, MPV 8fl, LDH level 500 U/l, platelet count /ml, WBC count /ml or haemoglobin level 10 g/l. When the impact of other factors was excluded, RDW 20% was associated with an increased mortality rate of 2.77-fold in patients with MM, an NLR 3 with an increased mortality rate of 1.67-fold and a nonepithelial subtype with an increased mortality rate of 1.52-fold. Survival curves for patients according to histopathological subtype (epithelial or nonepithelial), RDW (<20% and 20%) and NLR (<3 and 3) are presented in Figures 1 3; the number of patients with data available for each analysis varied. Association between baseline characteristics and prognostic parameters Tables 2 and 3 present the proportions of patients with different baseline characteristics according to NLR < 3 versus 3, and

5 558 Journal of International Medical Research 42(2) Table 1. Univariate and multivariate analyses results for potential prognostic parameters in patients with malignant mesothelioma (MM). Univariate analysis a Multivariate analysisa Variable O/N a Survival b 95% CI P-value HR 95.0% CI P-value Age, years, n ¼ 155 <60 60/ , NS NS 60 63/ Sex Male 71/ , NS NS Female 52/ Histopathological subtype, n ¼ 155 Epithelial 76/ , , Nonepithelial 47/ Platelet count, 10 3 /ml, n ¼ 155 < / 96/ , 1.25 NS / 27/ WBC count, per ml, n ¼ 154 < / , 1.43 NS / Serum LDH level, U/l, n ¼ 150 < / , 3.20 NS 500 9/ NLR, n ¼ 149 <3 61/ , , / PLR, n ¼ 149 < / , 1.63 NS / MPV, fl, n¼ 151 <8 62/ , 1.27 NS 8 59/ Haemoglobin level, g/l, n¼ 154 <10 10/ , 1.95 NS / RDW, %, n ¼ 152 <20 114/ , , /9 8.0 a Observed death n/total patient n; b Median survival (months). CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; MPV, mean platelet volume; NLR, neutrophil-tolymphocyte ratio; NS, not significant; PLR, platelet-to-lymphocyte ratio; RDW, red cell distribution width; WBC, white blood cell. a Cox proportional hazards regression model. according to RDW <20% versus 20%, respectively. The proportions of patients divided by age, sex, platelet count, LDH level, MPV, RDW or haemoglobin values were not significantly different between the two NLR groups. In contrast, significantly greater proportions of patients with a nonepithelioid histological subtype (P ¼ 0.007), a WBC count /ml (P < 0.000) and a PLR 300 (P ¼ 0.003) had NLR 3 compared with NLR <3 (Table 2). Significantly greater proportions of patients

6 Abakay et al. 559 Figure 1. Kaplan Meier survival curves according to histopathological subtype (epithelial and nonepithelial) in 155 patients with malignant mesothelioma (MM). When the impact of other factors was excluded, patients with a nonepithelial subtype (n ¼ 55) had a significantly increased mortality rate of 1.52-fold versus patients with an epithelial subtype (n ¼ 100) (P < 0.010; Cox proportional hazards regression model). The colour version of this figure is available at with epithelial subtype (P ¼ 0.018) and platelet count /ml (P ¼ 0.021) had RDW 20% compared with RDW <20% (Table 3). Discussion The EORTC and the Cancer and Leukemia Group B analysed large numbers of patients with MM and identified the following poor prognostic factors: 8,9 nonepithelioid histology; poor performance score; presence of chest pain; age >75 years; male sex; WBC count /l; platelet count > / ml; LDH >500 U/l. In the present univariate analysis there was a significant association between age >60 years and poor prognosis for MM. The patient cohort in the present study was stratified at 60 years, given the low mean age of our study group (58 years) and the short survival duration; few of our patients reached 75 years of age, despite Figure 2. Kaplan Meier survival curves according to red cell distribution width (RDW) (<20% and 20%) in 149 patients with malignant mesothelioma (MM). When the impact of other factors was excluded, patients with RDW 20% (n ¼ 9) had a significantly increased mortality rate of 2.77-fold versus patients with RDW <20% (n ¼ 143) (P < 0.010; Cox proportional hazards regression model). The colour version of this figure is available at this being considered as the threshold for poor prognosis in the international recommendations. 8,9 Inexpensive and easily detected prognostic parameters have not yet been developed for MM. Therefore, the present retrospective study investigated the relationship between potential prognostic indicators and survival in 155 patients with MM. In countries where people are exposed to asbestos through industrial practices, rates of MM are generally higher in men than in women. This is because men are more likely to work for longer time periods in such industries and are therefore more likely to have higher lifetime asbestos exposure rates. However, in our region, asbestos exposure is mostly environmental and begins at birth; it affects both sexes almost equally, because it is processed with water and people are

7 560 Journal of International Medical Research 42(2) Figure 3. Kaplan Meier survival curves according to neutrophil-to-lymphocyte ratio (NLR) (<3 and 3) in 149 patients with malignant mesothelioma (MM). When the impact of other factors was excluded, patients with NLR 3 (n ¼ 67) had a significantly increased mortality rate of 1.67-fold versus patients with NLR <3 (n ¼ 82) (P < 0.010; Cox proportional hazards regression model). The colour version of this figure is available at imr.sagepub.com. exposed via inhalation, in home environments. Some studies in our region have found male : female ratios of MM as close as ,5 In our study, the ratio was In our region MM is probably detected at lower ages than those observed elsewhere as a consequence of the high rate of environmental exposure described above. In one study performed in our region, the mean age of patients was 56 years. 30 The mean age of MM patients in our study is also relatively low, probably as a result of the regional environmental asbestos exposure. The mean survival time was 13.9 months. Of 11 potential prognostic factors assessed, the inflammatory markers NLR 3 and RDW 20% (in addition to the nonepithelial subtype), were effective indicators of MM prognosis in the multivariate analysis. Other markers (such as age, sex, LDH level, platelet count and WBC count) were not found to be prognostic indicators of MM. Studies have reported that the rate of mortality increased fold in patients with MM with NLR 3 versus <3, and that this difference was statistically significant. 17,19 Unal et al. found that pretreatment NLR measurements provided important prognostic results in patients with nonsmall cell lung cancer. 31 In other studies, the rate of mortality in patients with MM was increased fold with NLR 5 versus <5; this difference was also statistically significant. 16,18 Cedre s et al. 20 found that NLR 5 was an independent prognostic factor in patients with MM. In the present study, the rate of mortality increased 1.67-fold in patients with MM who had an NLR of 3 compared with NLR <3; mean duration of survival was 10.5 months in those with an NLR 3 and 14.9 months in those with an NLR <3. The NLR may, therefore, be viewed as an inexpensive predictor of MM prognosis at the time of diagnosis, and we postulate that the NLR level could be a factor to use as part of the decision making process, when considering aggressive or palliative treatment regimens for patients with MM. It is reasonable to assume that patients with MM with more advanced disease at the time of diagnosis may have a more excessive systemic inflammatory response and, therefore, a higher NLR. The histological subtype is well established in predicting prognosis in MM and many studies have found that the nonepithelial histological subtype is associated with a poor prognosis. 9,16,17 The multivariate analysis in the present study also confirmed this finding: the mortality rate increased 1.52-fold in patients with a nonepithelial subtype of MM. In complete blood count data, the RDW has been found to be increased in several inflammatory diseases. 24,32,33 However, the

8 Abakay et al. 561 Table 2. Baseline characteristics of patients with malignant mesothelioma (MM) based on neutrophil-to-lymphocyte ratio (NLR n ¼ 149). Variable NLR <3 n (%) NLR 3 n (%) P-value a Age, years <60 42 (51.2) 34 (50.7) NS (48.8) 33 (49.3) Sex Male 37 (45.1) 24 (35.8) NS Female 45 (54.9) 43 (45.2) Histopathological subtype Epithelial 61 (74.4) 36 (53.7) Nonepithelial 21 (25.6) 31 (46.3) Platelet count, 10 3 /ml < (81.7) 51 (76.1) NS (18.3) 16 (23.9) WBC count, per ml < (100.0) 55 (82.1) (17.9) Serum LDH level, U/l < (95.1) 58 (92.1) NS (4.9) 5 (7.9) PLR < (95.1) 53 (79.1) (4.9) 14 (20.9) MPV, fl <8 43 (52.4) 40 (60.6) NS 8 39 (47.6) 26 (39.4) RDW, % <20 75 (91.5) 65 (97.0) NS 20 7 (8.5) 2 (3.0) Haemoglobin level, g/l <10 8 (9.8) 3 (4.5) NS (90.2) 64 (95.5) LDH, lactate dehydrogenase; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; NS, nonsignificant; PLR, platelet-to-lymphocyte ratio; RDW, red cell distribution width; WBC, white blood cell. a 2 -test. association between a high RDW and overall prognosis in MM has not been widely investigated. In one investigation of patients with pulmonary embolism, RDW >15% was found to be a prognostic parameter in multivariate analysis, and RDW >15% increased the mortality rate 1.2-fold. 34 In another study of patients with communityacquired pneumonia, the 30-day mortality rate was significantly higher in those with a greater RDW. 35 In our study, mortality rates in patients with MM increased fold in those with RDW 20% versus <20%, and the mean survival time was 8 months in those with RDW 20%, compared with 13.9 months in those with RDW <20%: a difference that was statistically significant. This result may be due to the association between RDW and increased inflammation, and to chronic inflammation

9 562 Journal of International Medical Research 42(2) Table 3. Baseline characteristics of patients with malignant mesothelioma (MM), based on red cell distribution width (RDW; n ¼ 152). Variable RDW <20% n (%) RDW 20% n (%) P-value a Age, years <60 73 (51.0) 6 (66.7) NS (49.0) 3 (33.3) Sex Male 84 (58.7) 3 (33.3) NS Female 59 (41.3) 6 (66.7) Histopathological subtype Epithelial 90 (62.9) 9 (100.0) Nonepithelial 53 (37.1) 0 Platelet count, 10 3 /ml < (81.1) 4 (44.4) (18.9) 5 (55.6) WBC count, per ml < (92.3) 7 (87.5) NS (7.7) 1 (12.5) Serum LDH level, U/l < (94.2) 8 (88.9) NS (5.8) 1 (11.1) PLR < (88.6) 7 (77.8) NS (11.4) 2 (22.2) MPV, fl <8 80 (56.3) 4 (44.4) NS 8 62 (43.7) 5 (55.6) NLR <3 75 (53.6) 7 (77.8) NS 3 65 (46.4) 2 (22.2) Haemoglobin level, g/l <10 9 (6.3) 2 (22.2) NS (93.7) 7 (77.8) LDH, lactate dehydrogenase; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; NS, nonsignificant; PLR, platelet-to-lymphocyte ratio; RDW, red cell distribution width; WBC, white blood cell. a 2 -test. playing a key role in the development of MM. In our study, RDW 20% was associated with histopathological subtype and platelet count, whereas NLR 3 was associated with histopathological subtype, WBC count and PLR. These findings may be due to the associations between histopathological subtype, WBC count, platelet count and PLR, and poor prognosis of MM. 8,9,18 A limitation of our study is its retrospective nature, which focused on pretreatment information obtained from patients files. Moreover, treatment regimens and their outcomes were unavailable, since patient management was conducted in other clinics, such as oncology clinics, or in thoracic surgery. Another limitation is that we only became aware of the guidelines outlined by the REMARK initiative 36 after we had

10 Abakay et al. 563 undertaken the present study. As our study was retrospective, the patient data did not consistently include information on disease stage, comorbidities, performance status, chest pain, treatment regimens and other detailed results (which are recommended in the REMARK guidelines). Where possible, however, we had applied other recommendations of the REMARK initiative. In conclusion, the pathological role of chronic inflammation in the development of MM is well established. 13 Based on our results, inflammatory-based biomarkers may be predictive of survival. NLR, as an index of systemic inflammation, may be independently associated with survival in patients with MM. Both the NLR and the RDW may be useful prognostic markers: they are easily obtainable and were significant predictive factors for MM prognosis. The inexpensive nature and reproducibility of the complete blood count, which includes both NLR and RDW, should encourage their use in the clinical management of patients with MM. Both parameters may help in making the decision between aggressive or palliative treatment regimens. Declaration of conflicting interest The authors declare that there are no conflicts of interest. Funding This research received no specific grant from any funding agency in the public, commercial or notfor-profit sectors. References 1. Froudarakis ME. Pleural diseases in the molecular era time for more answers: introduction. Respiration 2012; 83: Tanrikulu AC, Senyigit A, Dagli CE, et al. Environmental malignant pleural mesothelioma in Southeast Turkey. Saudi Med J 2006; 27: Senyiğit A, Bayram H, Babayiğit C, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration 2000; 67: Senyiğit A, Babayig it C, Go kirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration 2000; 67: Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration 2010; 80: Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for Semin Oncol 1992; 19(suppl. 11): Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999; 25: Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia group B. Chest 1998; 113: Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: Hillegass JM, Shukla A, Lathrop SA, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 2010; 1203: 7 14.

11 564 Journal of International Medical Research 42(2) 14. Nowak AK, Stockler MR and Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 2004; 22: Robinson BW, Musk AW and Lake RA. Malignant mesothelioma. Lancet 2005; 366: Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16: Kao SC, Vardy J, Chatfield M, et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer 2013; 14: Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 2012; 7: Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-tolymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol 2011; 6: Cedre s S, Montero MA, Martinez P, et al. Exploratory analysis of activation of PTEN- PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012; 77: Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011; 60: Schweiger DJ. Red cell distribution width in sickle cell anemia. Am J Med Technol 1981; 47: Ani C and Ovbiagele B. Elevated red blood cell distribution width predicts mortality in persons with known stroke. J Neurol Sci 2009; 277: Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol 2009; 104: Wang F, Pan W, Pan S, et al. Red cell distribution width as a novel predictor of mortality in ICU patients. Ann Med 2011; 43: Bath PM and Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: Coban E and Adanır H. Platelet activation in patients with familial Mediterranean fever. Platelets 2008; 19: Makay B, Tu rkyilmaz Z and Unsal E. Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 2009; 28: Galateau-Salle FE. Pathology of malignant mesothelioma, 1st ed. New York: Springer- Verlag, 2006, p Abakay A, Tanrikulu AC, Kaplan MA, et al. Clinical characteristics and treatment outcomes of 132 patients with malignant mesothelioma. Lung India 2011; 28: Unal D, Eroglu C, Kurtul N, et al. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev 2013; 14: Montagnana M, Cervellin G, Meschi T, et al. The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med 2011; 50: Song CS, Park DI, Yoon MY, et al. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. Dig Dis Sci 2012; 57: Ozsu S, Abul Y, Gunaydin S, et al. Prognostic value of red cell distribution width in patients with pulmonary embolism. Clin Appl Thromb Hemost Epub ahead of

12 Abakay et al. 565 print 8, November DOI: / Lee JH, Chung HJ, Kim K, et al. Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia. Am J Emerg Med 2013; 31: McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumour Marker prognostic studies (REMARK). Eur J Cancer 2005; 41:

THE VALUE OF NEW INFLAMMATORY PARAMETERS IN MALIGNANT MESOTHELIOMA PROGNOSIS

THE VALUE OF NEW INFLAMMATORY PARAMETERS IN MALIGNANT MESOTHELIOMA PROGNOSIS Acta Medica Mediterranea, 2015, 31: 9 THE VALUE OF NEW INFLAMMATORY PARAMETERS IN MALIGNANT MESOTHELIOMA PROGNOSIS ABDULLAH CETIN TANRIKULU A, ICLAL HOCANLI A, AHMET YILMAZ B, FATIH METEROGLU C, MAHŞUK

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Characteristics of Malignant Pleural Mesothelioma in Women

Characteristics of Malignant Pleural Mesothelioma in Women Characteristics of Malignant Pleural Mesothelioma in Women Andrea S. Wolf, MD, MPH, William G. Richards, PhD, Tamara R. Tilleman, MD, PhD, Lucian Chirieac, MD, Shelley Hurwitz, PhD, Raphael Bueno, MD,

More information

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental

More information

RESEARCH ARTICLE. Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

RESEARCH ARTICLE. Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma DOI:http://dx.doi.org/10.7314/APJCP.2015.16.4.1403 RESEARCH ARTICLE Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma Halide Kaya 1 *, Melike Demir 1, Mahsuk Taylan 1, Cengizhan

More information

A new score predicting the survival of patients with spinal cord compression from myeloma

A new score predicting the survival of patients with spinal cord compression from myeloma A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy Lung Cancer International Volume 2015, Article ID 590148, 7 pages http://dx.doi.org/10.1155/2015/590148 Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Introduction Objective Methods Results Conclusion

Introduction Objective Methods Results Conclusion Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),

More information

Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkey

Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkey JBUON 2014; 19(1): 164-170 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Clinical characteristics, treatment and survival outcomes in malignant

More information

The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion

The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion Malaysian J Path01 2002; 24(1) : 53-58 The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion Pavai STHANESHWAR MD, Sook-Fan YAP FRCPath, FRCPA and Gita JAYARAM MDPath, MRCPath

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:

More information

Non-invasive diagnosis of pleural malignancies: The role of tumour markers

Non-invasive diagnosis of pleural malignancies: The role of tumour markers Lung Cancer (2008) 59, 350 354 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/lungcan Non-invasive diagnosis of pleural malignancies: The role of tumour markers Michel M.

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma

Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,

More information

P L E U R A L M E S O T H E L I O M A

P L E U R A L M E S O T H E L I O M A For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

A new score predicting the survival of patients with spinal cord compression from myeloma

A new score predicting the survival of patients with spinal cord compression from myeloma A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)

National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) Tracking Information Publication Number Manual Section Number 100-3 190.28 Manual Section Title Tumor Antigen by

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens

Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens Assunta De Rienzo, Ph.D. 1, Robert W. Cook, Ph.D. 2,

More information

PSA Screening for Prostate Cancer Information for Care Providers

PSA Screening for Prostate Cancer Information for Care Providers All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits

More information

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Eur Respir J 2012; 40: 185 189 DOI: 10.1183/09031936.00153611 CopyrightßERS 2012 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Ronald A.M. Damhuis*, Caroline

More information

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant

More information

Rare Thoracic Tumours

Rare Thoracic Tumours Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

Mesothelioma: Questions and Answers

Mesothelioma: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions

More information

Elevated Serum Lactate Dehydrogenase Values in Children with Multiorgan Involvements and Severe Febrile Illness

Elevated Serum Lactate Dehydrogenase Values in Children with Multiorgan Involvements and Severe Febrile Illness Iranian Journal of Pediatrics Society Volume 1, Number 1, 2007: 31-35 Original Article Elevated Serum Lactate Dehydrogenase Values in Children with Multiorgan Involvements and Severe Febrile Illness Farah

More information

Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD

Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD Public Outcomes Report Lung Cancer Submitted by Omar A. Majid, MD Lung cancer is the most common cancer-related cause of death among men and women. It has been estimated that there will be 226,1 new cases

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

DIAPHRAGM. DIAgnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma

DIAPHRAGM. DIAgnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma DIAPHRAGM DIAgnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma Kevin Blyth Consultant Respiratory Physician, Southern General Hospital NRS Research Fellow & Honorary Clinical

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

A 70-year old Man with Pleural Effusion

A 70-year old Man with Pleural Effusion Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Cancer research in the Midland Region the prostate and bowel cancer projects

Cancer research in the Midland Region the prostate and bowel cancer projects Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate

More information

prognostic scoring systems. We

prognostic scoring systems. We Thorax 2000;55:731 735 731 Original articles Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems J G Edwards, K R Abrams, J N Leverment,

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

Sepsis and the Clinical Laboratory

Sepsis and the Clinical Laboratory Sepsis and the Clinical Laboratory Alison Woodworth, PhD Department of Pathology, Microbiology, and Immunology Vanderbilt University Medical Center Nashville, TN Learning Objectives Outline the Pathogenesis

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Summary & Conclusion

Summary & Conclusion The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with

More information

Exploring the Role of Vitamins in Achieving a Healthy Heart

Exploring the Role of Vitamins in Achieving a Healthy Heart Exploring the Role of Vitamins in Achieving a Healthy Heart There are many avenues you can take to keep your heart healthy. The first step you should take is to have a medical professional evaluate the

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

Consortium led by Asbestos Diseases Research Institute (ADRI)

Consortium led by Asbestos Diseases Research Institute (ADRI) Translating Research into Better Outcomes for Patients with Asbestos-Related Disease and their Families Professor Nico van Zandwijk Consortium led by Asbestos Diseases Research Institute (ADRI) AUSTIN

More information

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland

More information

Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence

Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary

More information

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge. Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,

More information

Stephen R. Veach, M.D.

Stephen R. Veach, M.D. Stephen R. Veach, M.D. Memorial Sloan-Kettering Cancer Center International Oncology Programs 160 E. 53 rd Street New York, NY 10022 212-610 610-08780878 - tel 212-308 308-7063 - fax veachs@mskcc.org SCREENING

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

Kaiser Permanente Medical Group: Medical Legal Aspects of Mesothelioma

Kaiser Permanente Medical Group: Medical Legal Aspects of Mesothelioma Kaiser Permanente Medical Group: Medical Legal Aspects of Mesothelioma Presented by Steven Kazan, Managing Partner Kazan, McClain, Lyons, Greenwood & Harley, PLC Triangle Factory Fire March 25, 1911 Asbestos

More information

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form. General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,

More information

Table 2.4. Summary of design and findings from mesothelioma case-control studies

Table 2.4. Summary of design and findings from mesothelioma case-control studies categories Agudo et al. (2000) Barcelona and Cadiz, Spain 32 cases (77% males) of histologically con rmed malignant pleural mesothelioma identified from hospital in the region between //993 and 2/3/996.

More information

Treatment of mesothelioma in Bloemfontein, South Africa

Treatment of mesothelioma in Bloemfontein, South Africa European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,

More information

Kanıt: Klinik çalışmalarda ZYTIGA

Kanıt: Klinik çalışmalarda ZYTIGA mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen

More information

Primary Prevention of Cardiovascular Disease with a Mediterranean diet

Primary Prevention of Cardiovascular Disease with a Mediterranean diet Primary Prevention of Cardiovascular Disease with a Mediterranean diet Alejandro Vicente Carrillo, Brynja Ingadottir, Anne Fältström, Evelyn Lundin, Micaela Tjäderborn GROUP 2 Background The traditional

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

MEDICAL SCREENING PROTOCOL FOR THE FORMER WORKER MEDICAL SCREENING PROGRAM U.S. DEPARTMENT OF ENERGY

MEDICAL SCREENING PROTOCOL FOR THE FORMER WORKER MEDICAL SCREENING PROGRAM U.S. DEPARTMENT OF ENERGY MEDICAL SCREENING PROTOCOL FOR THE FORMER WORKER MEDICAL SCREENING PROGRAM U.S. DEPARTMENT OF ENERGY General Principles: 1) The purpose of the medical evaluation component of the U.S. Department of Energy

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Albumin and All-Cause Mortality Risk in Insurance Applicants

Albumin and All-Cause Mortality Risk in Insurance Applicants Copyright E 2010 Journal of Insurance Medicine J Insur Med 2010;42:11 17 MORTALITY Albumin and All-Cause Mortality Risk in Insurance Applicants Michael Fulks, MD; Robert L. Stout, PhD; Vera F. Dolan, MSPH

More information

CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal

CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:

More information

A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma

A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma Clinical Investigations DOI: 10.1159/000321370 Received: March 29, 2010 Accepted after revision: June 14, 2010 Published online: September 28, 2010 A Clinical, Radiographic and Laboratory Evaluation of

More information

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer

Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer Lung cancer accounts for 13% of all cancer diagnoses and is the leading cause of cancer death in both males

More information

Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer

Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer JBUON 2013; 18(3): 728-732 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Prognostic importance of the nutritional status and systemic inflammatory

More information

Lessons learned from the Western Australian experience with mesothelioma

Lessons learned from the Western Australian experience with mesothelioma Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information